LianBio

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, VRTX has a market cap of 120.6B. Regarding current trading prices, LIAN is priced at $0.32, while VRTX trades at $467.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas VRTX's P/E ratio is -122.62. In terms of profitability, LIAN's ROE is -0.36%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, LIAN is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check VRTX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, REGN has a market cap of 59.8B. Regarding current trading prices, LIAN is priced at $0.32, while REGN trades at $565.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas REGN's P/E ratio is 14.32. In terms of profitability, LIAN's ROE is -0.36%, compared to REGN's ROE of +0.15%. Regarding short-term risk, LIAN is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check REGN's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, LIAN is priced at $0.32, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas SGEN's P/E ratio is -57.19. In terms of profitability, LIAN's ROE is -0.36%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, LIAN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check SGEN's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ALNY has a market cap of 42.9B. Regarding current trading prices, LIAN is priced at $0.32, while ALNY trades at $327.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ALNY's P/E ratio is -156.58. In terms of profitability, LIAN's ROE is -0.36%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, LIAN is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ALNY's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ARGX has a market cap of 36.2B. Regarding current trading prices, LIAN is priced at $0.32, while ARGX trades at $593.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ARGX's P/E ratio is 36.13. In terms of profitability, LIAN's ROE is -0.36%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, LIAN is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ARGX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, BNTX has a market cap of 27.7B. Regarding current trading prices, LIAN is priced at $0.32, while BNTX trades at $113.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas BNTX's P/E ratio is -30.75. In terms of profitability, LIAN's ROE is -0.36%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, LIAN is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check BNTX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, SMMT has a market cap of 21.3B. Regarding current trading prices, LIAN is priced at $0.32, while SMMT trades at $27.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas SMMT's P/E ratio is -84.32. In terms of profitability, LIAN's ROE is -0.36%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, LIAN is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check SMMT's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, RPRX has a market cap of 20.6B. Regarding current trading prices, LIAN is priced at $0.32, while RPRX trades at $36.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas RPRX's P/E ratio is 14.97. In terms of profitability, LIAN's ROE is -0.36%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, LIAN is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check RPRX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, LIAN is priced at $0.32, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas BGNE's P/E ratio is -22.55. In terms of profitability, LIAN's ROE is -0.36%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, LIAN is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check BGNE's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, LIAN is priced at $0.32, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, LIAN's ROE is -0.36%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, LIAN is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check DNA-WT's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, GMAB has a market cap of 14.4B. Regarding current trading prices, LIAN is priced at $0.32, while GMAB trades at $23.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas GMAB's P/E ratio is 13.76. In terms of profitability, LIAN's ROE is -0.36%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, LIAN is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check GMAB's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, UTHR has a market cap of 13.7B. Regarding current trading prices, LIAN is priced at $0.32, while UTHR trades at $301.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas UTHR's P/E ratio is 12.14. In terms of profitability, LIAN's ROE is -0.36%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, LIAN is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check UTHR's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, INCY has a market cap of 13.6B. Regarding current trading prices, LIAN is priced at $0.32, while INCY trades at $69.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas INCY's P/E ratio is 351.03. In terms of profitability, LIAN's ROE is -0.36%, compared to INCY's ROE of +0.01%. Regarding short-term risk, LIAN is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check INCY's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, MRNA has a market cap of 13.2B. Regarding current trading prices, LIAN is priced at $0.32, while MRNA trades at $34.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas MRNA's P/E ratio is -3.91. In terms of profitability, LIAN's ROE is -0.36%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, LIAN is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check MRNA's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, LIAN is priced at $0.32, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas KRTX's P/E ratio is -28.09. In terms of profitability, LIAN's ROE is -0.36%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, LIAN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check KRTX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, EXEL has a market cap of 12.4B. Regarding current trading prices, LIAN is priced at $0.32, while EXEL trades at $44.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas EXEL's P/E ratio is 20.82. In terms of profitability, LIAN's ROE is -0.36%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, LIAN is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check EXEL's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, LIAN is priced at $0.32, while BMRN trades at $59.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas BMRN's P/E ratio is 21.86. In terms of profitability, LIAN's ROE is -0.36%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, LIAN is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check BMRN's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ASND has a market cap of 10.1B. Regarding current trading prices, LIAN is priced at $0.32, while ASND trades at $166.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ASND's P/E ratio is -24.56. In terms of profitability, LIAN's ROE is -0.36%, compared to ASND's ROE of +1.91%. Regarding short-term risk, LIAN is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ASND's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, LIAN is priced at $0.32, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas RXDX's P/E ratio is -56.47. In terms of profitability, LIAN's ROE is -0.36%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, LIAN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check RXDX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, TECH has a market cap of 9.2B. Regarding current trading prices, LIAN is priced at $0.32, while TECH trades at $59.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas TECH's P/E ratio is 70.82. In terms of profitability, LIAN's ROE is -0.36%, compared to TECH's ROE of +0.06%. Regarding short-term risk, LIAN is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check TECH's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, LIAN is priced at $0.32, while VRNA trades at $105.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas VRNA's P/E ratio is -52.65. In terms of profitability, LIAN's ROE is -0.36%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, LIAN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check VRNA's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, BBIO has a market cap of 8.8B. Regarding current trading prices, LIAN is priced at $0.32, while BBIO trades at $46.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas BBIO's P/E ratio is -13.01. In terms of profitability, LIAN's ROE is -0.36%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, LIAN is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check BBIO's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, LIAN is priced at $0.32, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas IMGN's P/E ratio is -111.55. In terms of profitability, LIAN's ROE is -0.36%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, LIAN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check IMGN's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, LIAN is priced at $0.32, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas BPMC's P/E ratio is -51.58. In terms of profitability, LIAN's ROE is -0.36%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, LIAN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check BPMC's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, LIAN is priced at $0.32, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas CERE's P/E ratio is -16.47. In terms of profitability, LIAN's ROE is -0.36%, compared to CERE's ROE of -0.43%. Regarding short-term risk, LIAN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check CERE's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, LIAN is priced at $0.32, while ROIV trades at $11.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ROIV's P/E ratio is -15.40. In terms of profitability, LIAN's ROE is -0.36%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, LIAN is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ROIV's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, LIAN is priced at $0.32, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, LIAN's ROE is -0.36%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, LIAN is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ROIVW's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, CORT has a market cap of 7.2B. Regarding current trading prices, LIAN is priced at $0.32, while CORT trades at $69.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas CORT's P/E ratio is 59.38. In terms of profitability, LIAN's ROE is -0.36%, compared to CORT's ROE of +0.20%. Regarding short-term risk, LIAN is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check CORT's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, HALO has a market cap of 7.2B. Regarding current trading prices, LIAN is priced at $0.32, while HALO trades at $58.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas HALO's P/E ratio is 15.49. In terms of profitability, LIAN's ROE is -0.36%, compared to HALO's ROE of +1.22%. Regarding short-term risk, LIAN is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check HALO's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, JAZZ has a market cap of 7.2B. Regarding current trading prices, LIAN is priced at $0.32, while JAZZ trades at $117.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas JAZZ's P/E ratio is 16.06. In terms of profitability, LIAN's ROE is -0.36%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, LIAN is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check JAZZ's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, RVMD has a market cap of 7.1B. Regarding current trading prices, LIAN is priced at $0.32, while RVMD trades at $37.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas RVMD's P/E ratio is -9.45. In terms of profitability, LIAN's ROE is -0.36%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, LIAN is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check RVMD's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, IONS has a market cap of 6.7B. Regarding current trading prices, LIAN is priced at $0.32, while IONS trades at $42.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas IONS's P/E ratio is -14.13. In terms of profitability, LIAN's ROE is -0.36%, compared to IONS's ROE of -0.92%. Regarding short-term risk, LIAN is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check IONS's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, MDGL has a market cap of 6.6B. Regarding current trading prices, LIAN is priced at $0.32, while MDGL trades at $297.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas MDGL's P/E ratio is -16.74. In terms of profitability, LIAN's ROE is -0.36%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, LIAN is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check MDGL's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, LIAN is priced at $0.32, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas RETA's P/E ratio is -66.29. In terms of profitability, LIAN's ROE is -0.36%, compared to RETA's ROE of +0.47%. Regarding short-term risk, LIAN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check RETA's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, AMRN has a market cap of 6.4B. Regarding current trading prices, LIAN is priced at $0.32, while AMRN trades at $15.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas AMRN's P/E ratio is -3.50. In terms of profitability, LIAN's ROE is -0.36%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, LIAN is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check AMRN's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, LIAN is priced at $0.32, while TGTX trades at $35.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas TGTX's P/E ratio is 147.60. In terms of profitability, LIAN's ROE is -0.36%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, LIAN is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check TGTX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, NUVL has a market cap of 5.8B. Regarding current trading prices, LIAN is priced at $0.32, while NUVL trades at $82.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas NUVL's P/E ratio is -18.44. In terms of profitability, LIAN's ROE is -0.36%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, LIAN is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check NUVL's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, RYTM has a market cap of 5.7B. Regarding current trading prices, LIAN is priced at $0.32, while RYTM trades at $84.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas RYTM's P/E ratio is -30.88. In terms of profitability, LIAN's ROE is -0.36%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, LIAN is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check RYTM's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, LIAN is priced at $0.32, while CRSP trades at $64.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas CRSP's P/E ratio is -14.42. In terms of profitability, LIAN's ROE is -0.36%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, LIAN is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check CRSP's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, LIAN is priced at $0.32, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, LIAN's ROE is -0.36%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, LIAN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ABCM's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, LIAN is priced at $0.32, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ISEE's P/E ratio is -22.44. In terms of profitability, LIAN's ROE is -0.36%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, LIAN is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ISEE's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, MRUS has a market cap of 5B. Regarding current trading prices, LIAN is priced at $0.32, while MRUS trades at $66.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas MRUS's P/E ratio is -16.06. In terms of profitability, LIAN's ROE is -0.36%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, LIAN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check MRUS's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, AXSM has a market cap of 5B. Regarding current trading prices, LIAN is priced at $0.32, while AXSM trades at $100.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas AXSM's P/E ratio is -17.47. In terms of profitability, LIAN's ROE is -0.36%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, LIAN is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check AXSM's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, TLX has a market cap of 4.8B. Regarding current trading prices, LIAN is priced at $0.32, while TLX trades at $13.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas TLX's P/E ratio is 157.78. In terms of profitability, LIAN's ROE is -0.36%, compared to TLX's ROE of +0.14%. Regarding short-term risk, LIAN is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check TLX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, PCVX has a market cap of 4.7B. Regarding current trading prices, LIAN is priced at $0.32, while PCVX trades at $36.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas PCVX's P/E ratio is -9.18. In terms of profitability, LIAN's ROE is -0.36%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, LIAN is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check PCVX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, SLNO has a market cap of 4.6B. Regarding current trading prices, LIAN is priced at $0.32, while SLNO trades at $86.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas SLNO's P/E ratio is -18.24. In terms of profitability, LIAN's ROE is -0.36%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, LIAN is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check SLNO's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, LIAN is priced at $0.32, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ALPN's P/E ratio is -101.52. In terms of profitability, LIAN's ROE is -0.36%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, LIAN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ALPN's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, LIAN is priced at $0.32, while CYTK trades at $37.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas CYTK's P/E ratio is -7.03. In terms of profitability, LIAN's ROE is -0.36%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, LIAN is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check CYTK's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, RNA has a market cap of 4.4B. Regarding current trading prices, LIAN is priced at $0.32, while RNA trades at $35.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas RNA's P/E ratio is -12.09. In terms of profitability, LIAN's ROE is -0.36%, compared to RNA's ROE of -0.27%. Regarding short-term risk, LIAN is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check RNA's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ALKS has a market cap of 4.3B. Regarding current trading prices, LIAN is priced at $0.32, while ALKS trades at $26.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ALKS's P/E ratio is 12.44. In terms of profitability, LIAN's ROE is -0.36%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, LIAN is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ALKS's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ADMA has a market cap of 4.3B. Regarding current trading prices, LIAN is priced at $0.32, while ADMA trades at $18.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ADMA's P/E ratio is 21.44. In terms of profitability, LIAN's ROE is -0.36%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, LIAN is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ADMA's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, MTSR has a market cap of 4.3B. Regarding current trading prices, LIAN is priced at $0.32, while MTSR trades at $40.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas MTSR's P/E ratio is -16.06. In terms of profitability, LIAN's ROE is -0.36%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, LIAN is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check MTSR's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, LIAN is priced at $0.32, while KRYS trades at $150.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas KRYS's P/E ratio is 35.40. In terms of profitability, LIAN's ROE is -0.36%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, LIAN is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check KRYS's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ABVX has a market cap of 4.2B. Regarding current trading prices, LIAN is priced at $0.32, while ABVX trades at $66.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ABVX's P/E ratio is -19.27. In terms of profitability, LIAN's ROE is -0.36%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, LIAN is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ABVX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, LIAN is priced at $0.32, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas OPT's P/E ratio is -1.52. In terms of profitability, LIAN's ROE is -0.36%, compared to OPT's ROE of +2.60%. Regarding short-term risk, LIAN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check OPT's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, LIAN is priced at $0.32, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas MRTX's P/E ratio is -4.82. In terms of profitability, LIAN's ROE is -0.36%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, LIAN is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check MRTX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ZLAB has a market cap of 4.1B. Regarding current trading prices, LIAN is priced at $0.32, while ZLAB trades at $38.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ZLAB's P/E ratio is -14.87. In terms of profitability, LIAN's ROE is -0.36%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, LIAN is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ZLAB's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, AKRO has a market cap of 4B. Regarding current trading prices, LIAN is priced at $0.32, while AKRO trades at $49.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas AKRO's P/E ratio is -13.48. In terms of profitability, LIAN's ROE is -0.36%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, LIAN is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check AKRO's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, LEGN has a market cap of 4B. Regarding current trading prices, LIAN is priced at $0.32, while LEGN trades at $42.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas LEGN's P/E ratio is -36.76. In terms of profitability, LIAN's ROE is -0.36%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, LIAN is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check LEGN's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, LIAN is priced at $0.32, while ACLX trades at $70.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ACLX's P/E ratio is -23.85. In terms of profitability, LIAN's ROE is -0.36%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, LIAN is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ACLX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ACAD has a market cap of 3.9B. Regarding current trading prices, LIAN is priced at $0.32, while ACAD trades at $22.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ACAD's P/E ratio is 16.97. In terms of profitability, LIAN's ROE is -0.36%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, LIAN is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ACAD's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, LIAN is priced at $0.32, while VKTX trades at $33.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas VKTX's P/E ratio is -22.35. In terms of profitability, LIAN's ROE is -0.36%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, LIAN is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check VKTX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, LIAN is priced at $0.32, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas RYZB's P/E ratio is -57.86. In terms of profitability, LIAN's ROE is -0.36%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, LIAN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check RYZB's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, LIAN is priced at $0.32, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas CBAY's P/E ratio is -32.81. In terms of profitability, LIAN's ROE is -0.36%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, LIAN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check CBAY's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, SRRK has a market cap of 3.7B. Regarding current trading prices, LIAN is priced at $0.32, while SRRK trades at $37.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas SRRK's P/E ratio is -15.27. In terms of profitability, LIAN's ROE is -0.36%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, LIAN is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check SRRK's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, PTCT has a market cap of 3.5B. Regarding current trading prices, LIAN is priced at $0.32, while PTCT trades at $44.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas PTCT's P/E ratio is 6.86. In terms of profitability, LIAN's ROE is -0.36%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, LIAN is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check PTCT's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, LIAN is priced at $0.32, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas SWTX's P/E ratio is -13.78. In terms of profitability, LIAN's ROE is -0.36%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, LIAN is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check SWTX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, LIAN is priced at $0.32, while MLTX trades at $54.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas MLTX's P/E ratio is -23.91. In terms of profitability, LIAN's ROE is -0.36%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, LIAN is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check MLTX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, LIAN is priced at $0.32, while PTGX trades at $55.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas PTGX's P/E ratio is 70.72. In terms of profitability, LIAN's ROE is -0.36%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, LIAN is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check PTGX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, LIAN is priced at $0.32, while KYMR trades at $45.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas KYMR's P/E ratio is -14.71. In terms of profitability, LIAN's ROE is -0.36%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, LIAN is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check KYMR's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, AAPG has a market cap of 3.1B. Regarding current trading prices, LIAN is priced at $0.32, while AAPG trades at $39.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas AAPG's P/E ratio is -50.40. In terms of profitability, LIAN's ROE is -0.36%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, LIAN is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check AAPG's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, LIAN is priced at $0.32, while CRNX trades at $30.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas CRNX's P/E ratio is -8.16. In terms of profitability, LIAN's ROE is -0.36%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, LIAN is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check CRNX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, IMVT has a market cap of 2.9B. Regarding current trading prices, LIAN is priced at $0.32, while IMVT trades at $17.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas IMVT's P/E ratio is -6.21. In terms of profitability, LIAN's ROE is -0.36%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, LIAN is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check IMVT's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, LIAN is priced at $0.32, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas MORF's P/E ratio is -14.88. In terms of profitability, LIAN's ROE is -0.36%, compared to MORF's ROE of -0.22%. Regarding short-term risk, LIAN is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check MORF's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, LIAN is priced at $0.32, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas MOR's P/E ratio is -12.64. In terms of profitability, LIAN's ROE is -0.36%, compared to MOR's ROE of -1.84%. Regarding short-term risk, LIAN is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check MOR's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, RXRX has a market cap of 2.8B. Regarding current trading prices, LIAN is priced at $0.32, while RXRX trades at $6.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas RXRX's P/E ratio is -3.61. In terms of profitability, LIAN's ROE is -0.36%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, LIAN is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check RXRX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, LIAN is priced at $0.32, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas KDNY's P/E ratio is -12.47. In terms of profitability, LIAN's ROE is -0.36%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, LIAN is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check KDNY's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, NAMS has a market cap of 2.6B. Regarding current trading prices, LIAN is priced at $0.32, while NAMS trades at $23.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas NAMS's P/E ratio is -12.83. In terms of profitability, LIAN's ROE is -0.36%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, LIAN is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check NAMS's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, LIAN is priced at $0.32, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas MYOV's P/E ratio is -14.05. In terms of profitability, LIAN's ROE is -0.36%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, LIAN is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check MYOV's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, LIAN is priced at $0.32, while LGND trades at $133.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas LGND's P/E ratio is -18.63. In terms of profitability, LIAN's ROE is -0.36%, compared to LGND's ROE of -0.16%. Regarding short-term risk, LIAN is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check LGND's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, NAMSW has a market cap of 2.6B. Regarding current trading prices, LIAN is priced at $0.32, while NAMSW trades at $12.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas NAMSW's P/E ratio is N/A. In terms of profitability, LIAN's ROE is -0.36%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, LIAN is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check NAMSW's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, LIAN is priced at $0.32, while RARE trades at $27.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas RARE's P/E ratio is -4.69. In terms of profitability, LIAN's ROE is -0.36%, compared to RARE's ROE of -1.86%. Regarding short-term risk, LIAN is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check RARE's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, LIAN is priced at $0.32, while MIRM trades at $51.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas MIRM's P/E ratio is -32.19. In terms of profitability, LIAN's ROE is -0.36%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, LIAN is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check MIRM's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, LIAN is priced at $0.32, while CPRX trades at $20.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas CPRX's P/E ratio is 13.36. In terms of profitability, LIAN's ROE is -0.36%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, LIAN is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check CPRX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, IBRX has a market cap of 2.5B. Regarding current trading prices, LIAN is priced at $0.32, while IBRX trades at $2.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas IBRX's P/E ratio is -5.02. In terms of profitability, LIAN's ROE is -0.36%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, LIAN is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check IBRX's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, APLS has a market cap of 2.5B. Regarding current trading prices, LIAN is priced at $0.32, while APLS trades at $19.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas APLS's P/E ratio is -10.88. In terms of profitability, LIAN's ROE is -0.36%, compared to APLS's ROE of -1.00%. Regarding short-term risk, LIAN is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check APLS's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, APGE has a market cap of 2.4B. Regarding current trading prices, LIAN is priced at $0.32, while APGE trades at $39.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas APGE's P/E ratio is -11.31. In terms of profitability, LIAN's ROE is -0.36%, compared to APGE's ROE of -0.19%. Regarding short-term risk, LIAN is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check APGE's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, LIAN is priced at $0.32, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas PRVB's P/E ratio is -16.43. In terms of profitability, LIAN's ROE is -0.36%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, LIAN is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check PRVB's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, LIAN is priced at $0.32, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas LBPH's P/E ratio is -26.66. In terms of profitability, LIAN's ROE is -0.36%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, LIAN is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check LBPH's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, XENE has a market cap of 2.3B. Regarding current trading prices, LIAN is priced at $0.32, while XENE trades at $30.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas XENE's P/E ratio is -9.41. In terms of profitability, LIAN's ROE is -0.36%, compared to XENE's ROE of -0.32%. Regarding short-term risk, LIAN is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check XENE's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, LIAN is priced at $0.32, while AGIO trades at $39.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas AGIO's P/E ratio is 3.47. In terms of profitability, LIAN's ROE is -0.36%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, LIAN is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check AGIO's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, LIAN is priced at $0.32, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas DICE's P/E ratio is -21.91. In terms of profitability, LIAN's ROE is -0.36%, compared to DICE's ROE of +0.56%. Regarding short-term risk, LIAN is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check DICE's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, BEAM has a market cap of 2.2B. Regarding current trading prices, LIAN is priced at $0.32, while BEAM trades at $21.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas BEAM's P/E ratio is -4.71. In terms of profitability, LIAN's ROE is -0.36%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, LIAN is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check BEAM's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, LIAN is priced at $0.32, while ARWR trades at $16.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas ARWR's P/E ratio is -12.69. In terms of profitability, LIAN's ROE is -0.36%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, LIAN is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check ARWR's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, HRMY has a market cap of 2.2B. Regarding current trading prices, LIAN is priced at $0.32, while HRMY trades at $36.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas HRMY's P/E ratio is 14.32. In terms of profitability, LIAN's ROE is -0.36%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, LIAN is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check HRMY's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, LIAN is priced at $0.32, while GLPG trades at $33.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas GLPG's P/E ratio is -6.35. In terms of profitability, LIAN's ROE is -0.36%, compared to GLPG's ROE of -0.06%. Regarding short-term risk, LIAN is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check GLPG's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, LIAN is priced at $0.32, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas CALT's P/E ratio is -22.73. In terms of profitability, LIAN's ROE is -0.36%, compared to CALT's ROE of -1.67%. Regarding short-term risk, LIAN is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check CALT's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, IDYA has a market cap of 2.1B. Regarding current trading prices, LIAN is priced at $0.32, while IDYA trades at $25.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas IDYA's P/E ratio is -6.71. In terms of profitability, LIAN's ROE is -0.36%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, LIAN is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check IDYA's competition here

LIAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LIAN stands at 34.2M. In comparison, IMRA has a market cap of 2.1B. Regarding current trading prices, LIAN is priced at $0.32, while IMRA trades at $42.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LIAN currently has a P/E ratio of -0.39, whereas IMRA's P/E ratio is N/A. In terms of profitability, LIAN's ROE is -0.36%, compared to IMRA's ROE of -0.41%. Regarding short-term risk, LIAN is more volatile compared to IMRA. This indicates potentially higher risk in terms of short-term price fluctuations for LIAN.Check IMRA's competition here